Severe Keratitis and Corneal Perforation by Paenibacillus glucanolyticus.


Journal

Cornea
ISSN: 1536-4798
Titre abrégé: Cornea
Pays: United States
ID NLM: 8216186

Informations de publication

Date de publication:
01 Aug 2021
Historique:
received: 12 08 2020
accepted: 12 09 2020
pubmed: 3 12 2020
medline: 15 12 2021
entrez: 2 12 2020
Statut: ppublish

Résumé

To report the first case of Paenibacillus glucanolyticus, a spore-forming bacteria, to be isolated in a human ocular infection. We describe a severe case of noncontact lens-related microbial keratitis due to P. glucanolyticus presenting with a large corneal abscess, severe ocular inflammation, and a large epithelial defect. The corneal scrapes with no growth initially cultured P. glucanolyticus on blood agar after 48 hours, with sensitivity to gentamicin and fluoroquinolones. No other organism was cultured. The patient had severe keratitis with a protracted course requiring cyanoacrylate glue patching because of keratolysis and perforation. The patient may benefit from a penetrating keratoplasty and extracapsular cataract extraction in due course to aid visual rehabilitation. This is the first reported ocular case of P. glucanolyticus demonstrating its bacterial virulence and pathogenic potential when infecting the cornea. Rapid identification with newer technology enable us to accurately identify these opportunistic bacteria and may give a more favorable visual outcome as correct sensitivities lead to timely treatment administration.

Identifiants

pubmed: 33264149
pii: 00003226-202108000-00022
doi: 10.1097/ICO.0000000000002584
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1062-1064

Informations de copyright

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors have no funding or conflicts of interest to disclose.

Références

Mathews SL, Grunden AM, Pawlak J. Degradation of lignocellulose and lignin by Paenibacillus glucanolyticus. Int Biodeterioration Biodegradation. 2016;110:79–86.
Mathews SL, Pawlak JJ, Grunden AM. Isolation of Paenibacillus glucanolyticus from pulp mill sources with potential to deconstruct pulping waste. Bioresour Technol. 2014;164:100–105.
Grady EN, MacDonald J, Liu L, et al. Current knowledge and perspectives of Paenibacillus: a review. Microb Cell Fact. 2016;15:203.
Alexander B, Priest FG. Bacillus glucanolyticus, a new species that degrades a variety of β-glucans. Int J Syst Evol Microbiol. 1989;39:112–115.
Ferrand J, Hadou T, Selton-Suty C, et al. Cardiac device-related endocarditis caused by Paenibacillus glucanolyticus. J Clin Microbiol. 2013;51:3439–3442.
Karsten E, Watson SL, Foster LJ. Diversity of microbial species implicated in keratitis: a review. Open Ophthalmol J. 2012;6:110.
Sahay P, Goel S, Nagpal R, et al. Infectious keratitis caused by rare and emerging micro-organisms. Curr Eye Res. 2020;6:761–773.
Austin A, Lietman T, Rose-Nussbaumer J. Update on the management of infectious keratitis. Ophthalmology. 2017;124:1678–1689.
Inturrisi CE, Colburn WA, Kaiko RF, et al. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther. 1987;41:392–401.
Tecce JJ, Cole JO, Mayer J, et al. Methadone effects on brain functioning and type A and B CNV shapes. Psychopharmacology (Berl). 1979;65:21–25.
Padhi S, Dash M, Sahu R, et al. Urinary tract infection due to Paenibacillus alvei in a chronic kidney disease: a rare case report. J Lab Physicians. 2013;5:133.
Ouyang J, Pei Z, Lutwick L, et al. Paenibacillus thiaminolyticus: a new cause of human infection, inducing bacteremia in a patient on hemodialysis. Ann Clin Lab Sci. 2008;38:393–400.
Schaefer F, Bruttin O, Zografos L, et al. Bacterial keratitis: a prospective clinical and microbiological study. Br J Ophthalmol. 2001;85:842–847.

Auteurs

Ali Hassan (A)

Cornea and External Eye Department, Moorfields Eye Hospital NHS Foundation Trust, St George's Hospital, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH